Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread

Cancer Cell

Volumn 26, Issue 1, 2014, Pages 77-91

  Pradeep, Sunila ^a   Kim, SeungW ^a   Wu, SherryY ^a   Nishimura, Masato ^a   Chaluvally Raghavan, Pradeep ^a   Miyake, Takahito ^a   Pecot, ChadV ^a   Kim, Sun Jin ^a   Choi, HyunJin ^a   Bischoff, FaridehZ ^b   Mayer, JulieAnn ^b   Huang, Li ^a   Nick, AlpaM ^a   Hall, CarolynS ^a   Rodriguez Aguayo, Cristian ^a   Zand, Behrouz ^a   Dalton, HeatherJ ^a   Arumugam, Thiruvengadam ^a   Lee, HoJeong ^a   Han, HeeDong ^a,c   Cho, MinSoon ^a   Rupaimoole, Rajesha ^a   Mangala, LingegowdaS ^a   Sehgal, Vasudha ^a   Oh, SangCheul ^a,d   Liu, Jinsong ^a   Lee, Ju Seog ^a   Coleman, RobertL ^a   Ram, Prahlad ^a   Lopez Berestein, Gabriel ^a   Fidler, IsaiahJ ^a   Sood, AnilK ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Biocept Inc   (United States)

^c Konkuk University School of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OMENTUM METASTASIS; OVARIAN CANCER CELL LINE; OVARY CANCER; PARABIOSIS; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC CELLS, CIRCULATING; NEUREGULIN-1; OMENTUM; OVARIAN NEOPLASMS; PARABIOSIS; PERITONEAL NEOPLASMS; RECEPTOR, ERBB-3; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904265681     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.002     Document Type: Article

References (36)

1. Adam L., Vadlamudi R., Kondapaka S.B., Chernoff J., Mendelsohn J., Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J.Biol. Chem. 1998, 273:28238-28246.
2. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., Sovak M.A., Yi J., Nycum L.R. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J.Clin. Oncol. 2012, 30:2039-2045.
3. Ahmed A.A., Lu Z., Jennings N.B., Etemadmoghadam D., Capalbo L., Jacamo R.O., Barbosa-Morais N., Le X.F., Vivas-Mejia P., Lopez-Berestein G., et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010, 18:109-121.
4. Akin O., Sala E., Moskowitz C.S., Ishill N., Soslow R.A., Chi D.S., Hricak H. Perihepatic metastases from ovarian cancer: Sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. Radiology 2008, 248:511-517.
5. Amler L.C. HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin. Biol. Ther. 2010, 10:1343-1355.
6. Apte S.M., Bucana C.D., Killion J.J., Gershenson D.M., Fidler I.J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol. Oncol. 2004, 93:78-86.
7. Burger R.A. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer. Ann. Oncol. 2011, 22(Suppl 8):viii65-viii68.
8. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
9. Castadot P., Magné N., Berghmans T., Drowart A., Baeyens L., Smets D., Van Houtte P. [Ovarian metastasis and lung adenocarcinoma: A case report]. Cancer Radiother. 2005, 9:183-186.
10. Gordon M.S., Matei D., Aghajanian C., Matulonis U.A., Brewer M., Fleming G.F., Hainsworth J.D., Garcia A.A., Pegram M.D., Schilder R.J., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J.Clin. Oncol. 2006, 24:4324-4332.
11. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., Nam E.J., Mora E.M., Stone R.L., Lu C., et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 2010, 16:3910-3922.
12. Heintz A.P.M., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., Ngan H.Y.S., Pecorelli S., Beller U. Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl 1):S161-S192.
13. Hou J., Dong J., Sun L., Geng L., Wang J., Zheng J., Li Y., Bridge J., Hinrichs S.H., Ding S.-J. Inhibition of phosphorylated c-Met inrhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J.Transl. Med. 2011, 9:64.
14. Kim S.J., Kim J.S., Papadopoulos J., Wook Kim S., Maya M., Zhang F., He J., Fan D., Langley R., Fidler I.J. Circulating monocytes expressing CD31: Implications for acute and chronic angiogenesis. Am. J. Pathol. 2009, 174:1972-1980.
15. Komurov K., White M.A., Ram P.T. Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data. PLoS Comput. Biol. 2010, 6:e1000889.
16. Komurov K., Dursun S., Erdin S., Ram P.T. NetWalker: A contextual network analysis tool for functional genomics. BMC Genomics 2012, 13:282.
17. Komurov K., Tseng J.T., Muller M., Seviour E.G., Moss T.J., Yang L., Nagrath D., Ram P.T. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol. Syst. Biol. 2012, 8:596.
18. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 gene targeting invivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
19. Ledermann, J.A., Perren, T., Raja1, F.A., Embleton, A. C., Rustin, G.J.S., Jayson, G., Kaye, S.B., Swart, A., Vaughan, M., and Hirte, H. (2013). Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. http://conference.ncri.org.uk/abstracts/2013/abstracts/ClinicalShowcase4.html.
20. Lee S.J., Ghosh S.C., Han H.D., Stone R.L., Bottsford-Miller J., Shen Y., Auzenne E.J., Lopez-Araujo A., Lu C., Nishimura M., et al. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin. Cancer Res. 2012, 18:4114-4121.
21. Lim M.C., Kang S., Lee K.S., Han S.-S., Park S.-J., Seo S.-S., Park S.-Y. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol. Oncol. 2009, 112:28-34.
22. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., Armaiz-Pena G.N., Hu W., Stone R.L., Munkarah A., et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18:185-197.
23. Markman M., Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J.Clin. Oncol. 2006, 24:988-994.
24. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 1985, 109:716-721.
25. Merrimack Pharmaceuticals (2013). Merrimack Pharmaceuticals Announces Results from a phase 2 study of MM-121 (SAR256212) in combination withpaclitaxel in patients with platinum-resistant or refractory advanced ovarian cancers. http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=801512.
26. Merritt W.M., Lin Y.G., Han L.Y., Kamat A.A., Spannuth W.A., Schmandt R., Urbauer D., Pennacchio L.A., Cheng J.-F., Nick A.M., et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N.Engl. J. Med. 2008, 359:2641-2650.
27. Naora H., Montell D.J. Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat. Rev. Cancer 2005, 5:355-366.
28. Pecot C.V., Bischoff F.Z., Mayer J.A., Wong K.L., Pham T., Bottsford-Miller J., Stone R.L., Lin Y.G., Jaladurgam P., Roh J.W., et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov 2011, 1:580-586.
29. Pecot C.V., Rupaimoole R., Yang D., Akbani R., Ivan C., Lu C., Wu S., Han H.D., Shah M.Y., Rodriguez-Aguayo C., et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 2013, 4:2427.
30. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., et al. A phase 3 trial of bevacizumab in ovarian cancer. N.Engl. J. Med. 2011, 365:2484-2496.
31. Phillips K.G., Velasco C.R., Li J., Kolatkar A., Luttgen M., Bethel K., Duggan B., Kuhn P., McCarty O.J.T. Optical quantification ofcellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol 2012, 2:72.
32. Schoeberl B., Faber A.C., Li D., Liang M.-C., Crosby K., Onsum M., Burenkova O., Pace E., Walton Z., Nie L., et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70:2485-2494.
33. Singh M., Zaino R.J., Filiaci V.J., Leslie K.K. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol. Oncol. 2007, 106:325-333.
34. Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., Rupairmoole R., Armaiz-Pena G.N., Pecot C.V., Coward J., et al. Paraneoplastic thrombocytosis in ovarian cancer. N.Engl. J. Med. 2012, 366:610-618.
35. Tarin D., Price J.E., Kettlewell M.G., Souter R.G., Vass A.C., Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984, 44:3584-3592.
36. Thaker P.H., Deavers M., Celestino J., Thornton A., Fletcher M.S., Landen C.N., Kinch M.S., Kiener P.A., Sood A.K. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 2004, 10:5145-5150.